Canon (OTCMKTS:CAJPY – Get Free Report) and Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) are both technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Insider and Institutional Ownership
9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 0.0% of Canon shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Canon and Mymd Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Canon | $29.46 billion | 0.85 | $2.22 billion | $2.54 | 11.28 |
| Mymd Pharmaceuticals | N/A | N/A | -$11.63 million | ($20.69) | -0.14 |
Canon has higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Canon, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Canon and Mymd Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Canon | 7.36% | 9.33% | 5.51% |
| Mymd Pharmaceuticals | N/A | -76.40% | -35.10% |
Risk & Volatility
Canon has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Canon and Mymd Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Canon | 0 | 1 | 0 | 0 | 2.00 |
| Mymd Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Summary
Canon beats Mymd Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Canon
Canon Inc., together with its subsidiaries, manufactures and sells office multifunction devices (MFDs), plain paper copying machines, laser and inkjet printers, cameras, diagnostic equipment, and lithography equipment. The company operates through four segments: Printing Business Unit, Imaging Business Unit, Medical Business Unit, and Industrial and Others Business Unit. The Printing Business Unit segment offers office MFDs, document solutions, laser multifunction printers, laser printers, inkjet printers, image scanners, calculators, digital continuous feed presses, digital sheet-fed presses, and large format printers. The Imaging Business Unit segment provides interchangeable-lens digital cameras, digital compact cameras, interchangeable lenses, compact photo printers, network cameras, video management and video content analytics software, digital camcorders, digital cinema cameras, broadcast equipment, and multimedia projectors. The Medical System Business Unit segment offers computed tomography systems, diagnostic ultrasound systems, diagnostic X-ray systems, magnetic resonance imaging systems, clinical chemistry analyzers, digital radiography systems, and ophthalmic equipment. The Industry and Others Business Unit segment provides semiconductor lithography equipment, flat panel display lithography equipment, vacuum thin-film deposition equipment, organic light-emitting diode display manufacturing equipment, die bonders, handy terminals, and document scanners. The company also provides maintenance services; and supplies replacement drums, parts, toners, and papers. It sells its products under the Canon brand through subsidiaries or independent distributors to dealers and retail outlets, as well as directly to end-users globally. Canon Inc. was founded in 1933 and is headquartered in Tokyo, Japan.
About Mymd Pharmaceuticals
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Canon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canon and related companies with MarketBeat.com's FREE daily email newsletter.
